SEATTLE--(BUSINESS WIRE)--Jun. 3, 2019--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage
immunotherapy company focused on developing innovative treatments for
cancer, autoimmune/inflammatory, and other diseases, today announced the
appointment of Wayne Gombotz, PhD as Chief Technology Officer. Dr.
Gombotz has more than 30 years’ experience in the biotech and pharma
industries and most recently served as the Chief Development Officer at
“We are pleased to welcome Wayne, a pioneer in the field and a key
contributor to the biotechnology industry here in Seattle, to Alpine,”
said Stanford Peng, MD PhD, President and Head of Research and
Development for Alpine. “Wayne’s deep expertise developing therapies in
oncology, infectious diseases, and autoimmune diseases will be a great
addition to the Alpine team as we continue to advance our lead programs
into and through the clinic.”
As Chief Development Officer at Immune Design, Dr. Gombotz was
responsible for advancing several immuno-oncology products from bench to
pivotal clinical trials. Prior to Immune Design, he held senior roles at
Omeros Corporation, Corixa Corporation, and Amgen (formerly Immunex),
where he played a major role in the development and launch of ENBREL®,
one of the top-selling drugs for psoriasis and multiple arthritis
Dr. Gombotz currently serves as an Advisory Board Member for the
University of Washington'sDepartment of Bioengineering and was a recent
recipient of the University of Washington College of Engineering’s 2019
Diamond Award for Distinguished Achievement in Industry.
Dr. Gombotz holds a PhD and MS in Bioengineering from the University of
Washington and a BA in biology from Colby College.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of
functional immune therapeutics. Alpine is employing directed evolution
to create potentially powerful multifunctional immunotherapies to
improve patients’ lives. Alpine has two lead programs. The first,
ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28
antagonist, engineered to reduce pathogenic immune responses. ALPN-101
is currently enrolling a Phase I healthy volunteer trial. The second,
ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and
PD-L1-dependent CD28 costimulator intended to combine checkpoint
inhibition with T cell costimulation - an approach currently absent from
approved checkpoint therapies. Alpine is backed by world-class research
and development capabilities, a highly-productive scientific platform,
and a proven management team. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005175/en/
Source: Alpine Immune Sciences, Inc.
Sheryl Seapy, 213-262-9390